# Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

> **NCT00794131** · PHASE1 · COMPLETED · sponsor: **Genelux GmbH** · enrollment: 43 (actual)

## Conditions studied

- Advanced Cancers (Solid Tumors)

## Interventions

- **BIOLOGICAL:** GL-ONC1

## Key facts

- **NCT ID:** NCT00794131
- **Lead sponsor:** Genelux GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00794131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00794131, "Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00794131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*